ReviewThe Lancet. Infectious diseases2019
Transmission of drug-resistant tuberculosis in HIV-endemic settings.
Review in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen.BMC infectious diseases · 2024Trial
- Literature Review on HIV-Viruses · 2026Review
- Characteristics of Primary and acquired multidrug-resistant tuberculosis patients in West Java, Indonesia.IJID regions · 2026Article
- Using causal frameworks to reduce bias in observational TB research: a comparison of model-building approaches.IJTLD open · 2026Article
- Missed PrEP opportunities and vulnerability to HIV during rifampicin-resistant tuberculosis treatment in South Africa.Frontiers in public health · 2026Article
- IFN-γ and IL-6 as Key Predicting Biomarkers for Active TB Among PLWH: Results from Four Machine Learning Methods.International journal of general medicine · 2026Article
- Viral control is required for intravenous BCG-mediated protection against tuberculosis in simian immunodeficiency virus-infected macaques.Research square · 2025Article
- Adaptive modeling of HIV-TB coinfection dynamics and intervention optimization.BMC public health · 2025Article
- Molecular Epidemiology ofMicroorganisms · 2025Review
- Global disease and economic burden of main mycobacterial infections in the working-age population from 1990 to 2021 with a forecast to 2045.Infectious medicine · 2025Article
- Recognising cutaneous tuberculosis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- Article
- A Multi Center, Epidemiological Study of Bone Tuberculosis in Southwest China from 2011 to 2023.Journal of epidemiology and global health · 2024Article
- Critical assessment of infants born to mothers with drug resistant tuberculosis.EClinicalMedicine · 2024Article
- Advances in technology for the laboratory diagnosis of individuals with HIV/AIDS coinfected withBiosafety and health · 2024Review
- Piloting "From the Inside Out" - a toolkit addressing tuberculosis-related self-stigma.BMC global and public health · 2024Article
- Trends in and Risk Factors for Drug Resistance inViruses · 2024Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
16 authors at 14 institutions in 5 countries.
Funding
Abstract
The emergence and expansion of the multidrug-resistant tuberculosis epidemic is a threat to the global control of tuberculosis. Multidrug-resistant tuberculosis is the result of the selection of resistance-conferring mutations during inadequate antituberculosis treatment. However, HIV has a profound effect on the natural history of tuberculosis, manifesting in an increased rate of disease progression, leading to increased transmission and amplification of multidrug-resistant tuberculosis. Interventions specific to HIV-endemic areas are urgently needed to block tuberculosis transmission. These interventions should include a combination of rapid molecular diagnostics and improved chemotherapy to shorten the duration of infectiousness, implementation of infection control measures, and active screening of multidrug-resistant tuberculosis contacts, with prophylactic regimens for individuals without evidence of disease. Development and improvement of the efficacy of interventions will require a greater understanding of the factors affecting the transmission of multidrug-resistant tuberculosis in HIV-endemic settings, including population-based molecular epidemiology studies. In this Series article, we review what we know about the transmission of multidrug-resistant tuberculosis in settings with high burdens of HIV and define the research priorities required to develop more effective interventions, to diminish ongoing transmission and the amplification of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.